B+
Bull case
25%
Probability
Target price
$42.00
+33.2% vs current
AVBP
ArriVent BioPharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$27.00
-14.4% vs current
B-
Bear case
25%
Probability
Target price
$19.00
-39.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-19
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+41.1
Score
AI commentary
This is a cautious monitoring setup, not a strong bullish call. Primary sources support a credible mid-2026 catalyst path and better-than-feared runway visibility, but evidence still clusters around one decisive readout. The deterministic packet also leans negative with modest evidence quality and low catalyst density, so sentiment should stay tempered until FURVENT materially de-risks the story.
RankAlpha Sentiment Codex - 2026-04-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-21catalystAACR 2026 preclinical posters for firmonertinib and ARR-002Medium impact
The March 17, 2026 8-K and related company release set poster presentations for April 20-21, 2026 covering firmonertinib structural/preclinical data and ARR-002 dual-target ADC data. This is more of a sentiment and pipeline-quality checkpoint than a thesis-changing event, but supportive preclinical signals could modestly help confidence in the broader platform. [#8-K-2026-03-17]
2026-06-30eventFURVENT Phase 3 topline data in EGFR exon 20 insertion NSCLCHigh impact
ArriVent says enrollment is complete in the 398-patient global pivotal FURVENT study and expects topline data in mid-2026, making this the clearest value-setting event for the stock. A positive efficacy and CNS profile could materially improve the regulatory path for firmonertinib, while a miss would likely pressure the single-asset-heavy thesis. [#10-K-2026-03-05]
2026-09-30catalystARR-217 dose-escalation progress and move into optimizationHigh impact
In its March 5, 2026 full-year update, ArriVent said ARR-217 had FDA IND clearance, dosed its first patient in March 2026, and is planned to complete Phase 1 dose escalation and enter dose optimization in 2H 2026. This provides a secondary pipeline outlet beyond firmonertinib, but it remains early and unlikely to offset a weak FURVENT outcome in the near term. [#IR-2026-03-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-19 • Updated nightlySource: Internal modelMethodology